Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREArtificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREIQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBackground: Medical oncologists focused on advancing research and treatment options for patients recognize the importance of balancing investment in innovative therapeutics and providing patients access to these with the need to ensure the sustainability of health systems. The Horizon Europe Mission on Cancer and Europe’s Beating Cancer Plan as well as the European Pharmaceutical Strategy are all intended to bring improved outcomes to patients but often with timelines that stretch decades into the future. At the same time, investment levels are constrained by macroeconomic factors, and policymakers must make tough decisions as to where to invest to achieve maximum societal returns.
This symposium will bring together a multi-stakeholder panel to propose ways to accelerate the impact of cost-effective efforts to improve cancer outcomes five-fold – reducing what might take 50 years to only 10 years. It aligns with the aims of the ESMO Congress in Madrid – Good Science, Better Medicine, Best Practice.
Register to attend in-person or virtually.
Format: The symposium will begin with a short 15-minute presentation by the IQVIA Institute to set the stage and provide an evidence base that can inform the subsequent discussion. Panelists will be invited to share their perspectives and respond to questions. We expect an interactive, engaging dialogue.
Potential areas of discussion:
Diagnostics for the precision medicine era
What bottlenecks to optimal care exist in the diagnostics and care delivery area and how much impact could be achieved by reducing or removing these barriers within a decade?
What stops every European patient from getting a modern diagnostic test?
What is the cost of "not testing"?
Where are there low-hanging fruit policy makers should prioritize for improvement and investment that can provide rapid and broad improvement to patient care?
Driving improvements in surgery and radiotherapy What potential do these modalities have to improve cancer care?
Are we making the right level of investment in public R&D efforts relative to their potential?
How do we better champion the development and implementation of innovative surgical and radiotherapy approaches?
How can we more quickly disseminate emerging best practice?
Conducting pragmatic trials to accelerate repurposing and label expansion
Where are the opportunities to bring existing therapies more quickly to patients?
How might pragmatic clinical trials be designed to accelerate evidence development and what magnitude of benefit can be achieved?
What regulatory changes or flexibility might be needed to accommodate non-traditional trial approaches?
What lessons have already been learned about pragmatic trials that can applied more broadly?